{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:52:43Z","timestamp":1783032763683,"version":"3.54.6"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,18]]},"DOI":"10.7759\/cureus.97193","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:13:31Z","timestamp":1763532811000},"source":"Crossref","is-referenced-by-count":2,"title":["Expanding the Therapeutic Landscape: Sodium-Glucose Co-transporter 2 Inhibitors in Kidney Transplant Recipients"],"prefix":"10.7759","author":[{"given":"Alishba","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Mohsin","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwan","family":"Hamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens PE","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, et al.. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024, 105:S117-314. 10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go AS","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004, 351:1296-305. 10.1056\/NEJMoa041031","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5500\/wjt.v13.i5.239","article-title":"Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients","volume":"13","author":"Ramakrishnan P","year":"2023","unstructured":"Ramakrishnan P, Garg N, Pabich S, Mandelbrot DA, Swanson KJ. Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients. World J Transplant. 2023, 13:239-49. 10.5500\/wjt.v13.i5.239","journal-title":"World J Transplant"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54171-8","article-title":"The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients","volume":"15","author":"Sheu JY","year":"2024","unstructured":"Sheu JY, Chang LY, Chen JY, Pan HC, Tseng CS, Chueh JS, Wu VC. The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients. Nat Commun. 2024, 15:10043. 10.1038\/s41467-024-54171-8","journal-title":"Nat Commun"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al.. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023, 388:117-27. 10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100851","article-title":"SGLT2 inhibitor use in chronic kidney disease: supporting cardiovascular, kidney, and metabolic health","volume":"6","author":"Madero M","year":"2024","unstructured":"Madero M, Chertow GM, Mark PB. SGLT2 inhibitor use in chronic kidney disease: supporting cardiovascular, kidney, and metabolic health. Kidney Med. 2024, 6:100851. 10.1016\/j.xkme.2024.100851","journal-title":"Kidney Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) Diabetes Work Group, Rossing P, Caramori ML, et al.: KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022, 102:S1-27. 10.1016\/j.kint.2022.06.008","journal-title":"Kidney Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent C","year":"2022","unstructured":"Baigent C, Emberson J, Haynes R, et al.. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022, 400:1788-801. 10.1016\/S0140-6736(22)02074-8","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.10.031","article-title":"Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial","volume":"99","author":"Kraus BJ","year":"2021","unstructured":"Kraus BJ, Weir MR, Bakris GL, et al.. Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021, 99:750-62. 10.1016\/j.kint.2020.10.031","journal-title":"Kidney Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2022030306","article-title":"Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in patients with CKD","volume":"33","author":"Jongs N","year":"2022","unstructured":"Jongs N, Chertow GM, Greene T, et al.. Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in patients with CKD. J Am Soc Nephrol. 2022, 33:2094-107. 10.1681\/ASN.2022030306","journal-title":"J Am Soc Nephrol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2019.11.007","article-title":"Outcomes of SGLT2 inhibitors use in diabetic renal transplant patients","volume":"52","author":"AlKindi F","year":"2020","unstructured":"AlKindi F, Al-Omary HL, Hussain Q, Al Hakim M, Chaaban A, Boobes Y. Outcomes of SGLT2 inhibitors use in diabetic renal transplant patients. Transplant Proc. 2020, 52:175-8. 10.1016\/j.transproceed.2019.11.007","journal-title":"Transplant Proc"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf046","article-title":"Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease","volume":"40","author":"Bakker WM","year":"2025","unstructured":"Bakker WM, Heerspink HJ, Berger SP, et al.. Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease. Nephrol Dial Transplant. 2025, 40:1746-55. 10.1093\/ndt\/gfaf046","journal-title":"Nephrol Dial Transplant"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fneph.2024.1332397","article-title":"SGLT2 inhibitors in diabetic and non-diabetic kidney transplant recipients: current knowledge and expectations","volume":"4","author":"Polychronopoulou E","year":"2024","unstructured":"Polychronopoulou E, Bourdon F, Teta D. SGLT2 inhibitors in diabetic and non-diabetic kidney transplant recipients: current knowledge and expectations. Front Nephrol. 2024, 4:1332397. 10.3389\/fneph.2024.1332397","journal-title":"Front Nephrol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57030250","article-title":"New-onset diabetes after kidney transplantation","volume":"57","author":"Ponticelli C","year":"2021","unstructured":"Ponticelli C, Favi E, Ferraresso M. New-onset diabetes after kidney transplantation. Medicina (Kaunas). 2021, 57:250. 10.3390\/medicina57030250","journal-title":"Medicina (Kaunas)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2017.10.011","article-title":"The global epidemiology of diabetes and kidney disease","volume":"25","author":"Koye DN","year":"2018","unstructured":"Koye DN, Magliano DJ, Nelson RG, Pavkov ME. The global epidemiology of diabetes and kidney disease. Adv Chronic Kidney Dis. 2018, 25:121-32. 10.1053\/j.ackd.2017.10.011","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020470","article-title":"Diabetic kidney disease in post-transplant diabetes mellitus: causes, treatment and outcomes","volume":"11","author":"Lim LM","year":"2023","unstructured":"Lim LM, Chang JM, Kuo HT. Diabetic kidney disease in post-transplant diabetes mellitus: causes, treatment and outcomes. Biomedicines. 2023, 11:470. 10.3390\/biomedicines11020470","journal-title":"Biomedicines"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0137-7","article-title":"Post-transplant diabetes mellitus in patients with solid organ transplants","volume":"15","author":"Jenssen T","year":"2019","unstructured":"Jenssen T, Hartmann A. Post-transplant diabetes mellitus in patients with solid organ transplants. Nat Rev Endocrinol. 2019, 15:172-88. 10.1038\/s41574-018-0137-7","journal-title":"Nat Rev Endocrinol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31825f4434","article-title":"Early posttransplantation hyperglycemia in kidney transplant recipients is associated with overall long-term graft losses","volume":"94","author":"Valderhaug TG","year":"2012","unstructured":"Valderhaug TG, Hjelmes\u00e6th J, Jenssen T, R\u00f8islien J, Leivestad T, Hartmann A. Early posttransplantation hyperglycemia in kidney transplant recipients is associated with overall long-term graft losses. Transplantation. 2012, 94:714-20. 10.1097\/TP.0b013e31825f4434","journal-title":"Transplantation"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-021-00742-4","article-title":"Impact of diabetes mellitus developing after kidney transplantation on patient mortality and graft survival: a meta-analysis of adjusted data","volume":"13","author":"Lin H","year":"2021","unstructured":"Lin H, Yan J, Yuan L, et al.. Impact of diabetes mellitus developing after kidney transplantation on patient mortality and graft survival: a meta-analysis of adjusted data. Diabetol Metab Syndr. 2021, 13:126. 10.1186\/s13098-021-00742-4","journal-title":"Diabetol Metab Syndr"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.628936","article-title":"Prevention and management of transplant-associated diabetes","volume":"12","author":"Jenssen T","year":"2011","unstructured":"Jenssen T, Hartmann A. Prevention and management of transplant-associated diabetes. Expert Opin Pharmacother. 2011, 12:2641-55. 10.1517\/14656566.2011.628936","journal-title":"Expert Opin Pharmacother"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/tri.12112","article-title":"Diagnosis, management and treatment of glucometabolic disorders emerging after kidney transplantation: a position statement from the Nordic Transplantation Societies","volume":"26","author":"Hornum M","year":"2013","unstructured":"Hornum M, Lindahl JP, von Zur-M\u00fchlen B, Jenssen T, Feldt-Rasmussen B. Diagnosis, management and treatment of glucometabolic disorders emerging after kidney transplantation: a position statement from the Nordic Transplantation Societies. Transpl Int. 2013, 26:1049-60. 10.1111\/tri.12112","journal-title":"Transpl Int"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp566","article-title":"Glucose tolerance before and after renal transplantation","volume":"25","author":"Bergrem HA","year":"2010","unstructured":"Bergrem HA, Valderhaug TG, Hartmann A, Bergrem H, Hjelmesaeth J, Jenssen T. Glucose tolerance before and after renal transplantation. Nephrol Dial Transplant. 2010, 25:985-92. 10.1093\/ndt\/gfp566","journal-title":"Nephrol Dial Transplant"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad258","article-title":"International consensus on post-transplantation diabetes mellitus","volume":"39","author":"Sharif A","year":"2024","unstructured":"Sharif A, Chakkera H, de Vries AP, et al.. International consensus on post-transplantation diabetes mellitus. Nephrol Dial Transplant. 2024, 39:531-49. 10.1093\/ndt\/gfad258","journal-title":"Nephrol Dial Transplant"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021010127","article-title":"Early postoperative basal insulin therapy versus standard of care for the prevention of diabetes mellitus after kidney transplantation: a multicenter randomized trial","volume":"32","author":"Schwaiger E","year":"2021","unstructured":"Schwaiger E, Krenn S, Kurnikowski A, et al.. Early postoperative basal insulin therapy versus standard of care for the prevention of diabetes mellitus after kidney transplantation: a multicenter randomized trial. J Am Soc Nephrol. 2021, 32:2083-98. 10.1681\/ASN.2021010127","journal-title":"J Am Soc Nephrol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1321-2","article-title":"Transplantation and diabetes (Transdiab): a pilot randomised controlled trial of metformin in impaired glucose tolerance after kidney transplantation","volume":"20","author":"Alnasrallah B","year":"2019","unstructured":"Alnasrallah B, Goh TL, Chan LW, Manley P, Pilmore H. Transplantation and diabetes (Transdiab): a pilot randomised controlled trial of metformin in impaired glucose tolerance after kidney transplantation. BMC Nephrol. 2019, 20:147. 10.1186\/s12882-019-1321-2","journal-title":"BMC Nephrol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad063c_3629","article-title":"Effects of metformin in kidney transplant recipients taking tacrolimus with post-transplantation diabetes mellitus","volume":"38","author":"Jung J","year":"2023","unstructured":"Jung J, Lee J, Park JY, Kim H. Effects of metformin in kidney transplant recipients taking tacrolimus with post-transplantation diabetes mellitus. Nephrol Dial Transplant. 2023, 38:gfad063c_3629. 10.1093\/ndt\/gfad063c_3629","journal-title":"Nephrol Dial Transplant"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft536","article-title":"Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation","volume":"29","author":"Str\u00f8m Halden TA","year":"2014","unstructured":"Str\u00f8m Halden TA, \u00c5sberg A, Vik K, Hartmann A, Jenssen T. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. Nephrol Dial Transplant. 2014, 29:926-33. 10.1093\/ndt\/gft536","journal-title":"Nephrol Dial Transplant"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000004373","article-title":"Sitagliptin versus placebo to reduce the incidence and severity of posttransplant diabetes mellitus after kidney transplantation: a single-center, randomized, double-blind controlled trial","volume":"107","author":"Delos Santos RB","year":"2023","unstructured":"Delos Santos RB, Hagopian JC, Chen L, Ramakrishnan M, Wijeweera H, Klein CL, Brennan DC. Sitagliptin versus placebo to reduce the incidence and severity of posttransplant diabetes mellitus after kidney transplantation: a single-center, randomized, double-blind controlled trial. Transplantation. 2023, 107:1180-7. 10.1097\/TP.0000000000004373","journal-title":"Transplantation"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2025.02.031","article-title":"Glucagon-like peptide-1 receptor agonists compared to insulin for post-transplant diabetes mellitus after solid organ transplant","volume":"57","author":"Gordon R","year":"2025","unstructured":"Gordon R, Kerr J, Feist A, Mariski M, Kozuch J. Glucagon-like peptide-1 receptor agonists compared to insulin for post-transplant diabetes mellitus after solid organ transplant. Transplant Proc. 2025, 57:683-7. 10.1016\/j.transproceed.2025.02.031","journal-title":"Transplant Proc"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae018","article-title":"Safety and efficacy of glucagon-like peptide-1 receptor agonists among kidney transplant recipients: a systematic review and meta-analysis","volume":"17","author":"Krisanapan P","year":"2024","unstructured":"Krisanapan P, Suppadungsuk S, Sanpawithayakul K, et al.. Safety and efficacy of glucagon-like peptide-1 receptor agonists among kidney transplant recipients: a systematic review and meta-analysis. Clin Kidney J. 2024, 17:sfae018. 10.1093\/ckj\/sfae018","journal-title":"Clin Kidney J"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1159\/000501854","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus","volume":"44","author":"Mahling M","year":"2019","unstructured":"Mahling M, Schork A, Nadalin S, Fritsche A, Heyne N, Guthoff M. Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus. Kidney Blood Press Res. 2019, 44:984-92. 10.1159\/000501854","journal-title":"Kidney Blood Press Res"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.185","article-title":"Early initiation of sodium-glucose linked transporter inhibitors (SGLT-2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients","volume":"4","author":"Song CC","year":"2021","unstructured":"Song CC, Brown A, Winstead R, Yakubu I, Demehin M, Kumar D, Gupta G. Early initiation of sodium-glucose linked transporter inhibitors (SGLT-2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients. Endocrinol Diabetes Metab. 2021, 4:e00185. 10.1002\/edm2.185","journal-title":"Endocrinol Diabetes Metab"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001228","article-title":"Safety and efficacy of sodium-glucose cotransporter 2 inhibitors in kidney transplant recipients with pretransplant type 2 diabetes mellitus: a retrospective, single-center, inverse probability of treatment weighting analysis of 85 transplant patients","volume":"7","author":"Hisadome Y","year":"2021","unstructured":"Hisadome Y, Mei T, Noguchi H, et al.. Safety and efficacy of sodium-glucose cotransporter 2 inhibitors in kidney transplant recipients with pretransplant type 2 diabetes mellitus: a retrospective, single-center, inverse probability of treatment weighting analysis of 85 transplant patients. Transplant Direct. 2021, 7:e772. 10.1097\/TXD.0000000000001228","journal-title":"Transplant Direct"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14718","article-title":"Sodium-glucose cotransporter 2 inhibitors for treatment of diabetes mellitus after kidney transplantation","volume":"36","author":"Lemke A","year":"2022","unstructured":"Lemke A, Brokmeier HM, Leung SB, et al.. Sodium-glucose cotransporter 2 inhibitors for treatment of diabetes mellitus after kidney transplantation. Clin Transplant. 2022, 36:e14718. 10.1111\/ctr.14718","journal-title":"Clin Transplant"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.15144","article-title":"Sodium\u2010glucose co\u2010transporter 2 inhibitors & glucagon\u2010like peptide\u20101 receptor agonists, efficacy & safety in diabetic kidney transplant recipients","volume":"37","author":"Mahmoud T","year":"2023","unstructured":"Mahmoud T, Yagan J, Hasan A, et al.. Sodium\u2010glucose co\u2010transporter 2 inhibitors &amp; glucagon\u2010like peptide\u20101 receptor agonists, efficacy &amp; safety in diabetic kidney transplant recipients. Clin Transplant. 2023, 37:e15144. 10.1111\/ctr.15144","journal-title":"Clin Transplant"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15223","article-title":"Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety","volume":"19","author":"Schwaiger E","year":"2019","unstructured":"Schwaiger E, Burghart L, Signorini L, et al.. Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. Am J Transplant. 2019, 19:907-19. 10.1111\/ajt.15223","journal-title":"Am J Transplant"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.4103\/ijn.IJN_2_18","article-title":"Efficacy and safety of canagliflozin in kidney transplant patients","volume":"29","author":"Shah M","year":"2019","unstructured":"Shah M, Virani Z, Rajput P, Shah B. Efficacy and safety of canagliflozin in kidney transplant patients. Indian J Nephrol. 2019, 29:278-81. 10.4103\/ijn.IJN_2_18","journal-title":"Indian J Nephrol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-023-03645-7","article-title":"The results of SGLT-2 inhibitors use in kidney transplantation: 1-year experiences from two centers","volume":"55","author":"Demir ME","year":"2023","unstructured":"Demir ME, \u00d6zler TE, Merhametsiz \u00d6, et al.. The results of SGLT-2 inhibitors use in kidney transplantation: 1-year experiences from two centers. Int Urol Nephrol. 2023, 55:2989-99. 10.1007\/s11255-023-03645-7","journal-title":"Int Urol Nephrol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0093","article-title":"Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus","volume":"42","author":"Halden TA","year":"2019","unstructured":"Halden TA, Kvitne KE, Midtvedt K, et al.. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care. 2019, 42:1067-74. 10.2337\/dc19-0093","journal-title":"Diabetes Care"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad007","article-title":"Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes: an observational multicentre study","volume":"16","author":"S\u00e1nchez Fructuoso AI","year":"2023","unstructured":"S\u00e1nchez Fructuoso AI, Bedia Raba A, Banegas Deras E, et al.. Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes: an observational multicentre study. Clin Kidney J. 2023, 16:1022-34. 10.1093\/ckj\/sfad007","journal-title":"Clin Kidney J"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000004228","article-title":"The efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients","volume":"106","author":"Lim JH","year":"2022","unstructured":"Lim JH, Kwon S, Jeon Y, et al.. The efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients. Transplantation. 2022, 106:e404-12. 10.1097\/TP.0000000000004228","journal-title":"Transplantation"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2025.03.019","article-title":"The impact of sodium-glucose cotransporter-2 inhibitors on dialysis risk and mortality in kidney transplant patients with diabetes","volume":"25","author":"Yen FS","year":"2025","unstructured":"Yen FS, Hsu CC, Yeh YK, Cheng WY, Liao PL, Hwu CM, Wei JC. The impact of sodium-glucose cotransporter-2 inhibitors on dialysis risk and mortality in kidney transplant patients with diabetes. Am J Transplant. 2025, 25:1954-64. 10.1016\/j.ajt.2025.03.019","journal-title":"Am J Transplant"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020, 383:1413-24. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.05.022","article-title":"Cardioprotective effect of SGLT2 inhibitor in diabetic kidney transplant recipients: a multicenter propensity score matched study","volume":"9","author":"Lim JH","year":"2024","unstructured":"Lim JH, Kwon S, Seo YJ, et al.. Cardioprotective effect of SGLT2 inhibitor in diabetic kidney transplant recipients: a multicenter propensity score matched study. Kidney Int Rep. 2024, 9:2474-83. 10.1016\/j.ekir.2024.05.022","journal-title":"Kidney Int Rep"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12104","article-title":"Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease","volume":"76","author":"Cravedi P","year":"2013","unstructured":"Cravedi P, Remuzzi G. Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. Br J Clin Pharmacol. 2013, 76:516-23. 10.1111\/bcp.12104","journal-title":"Br J Clin Pharmacol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01310211","article-title":"Posttransplantation proteinuria: an approach to diagnosis and management","volume":"6","author":"Shamseddin MK","year":"2011","unstructured":"Shamseddin MK, Knoll GA. Posttransplantation proteinuria: an approach to diagnosis and management. Clin J Am Soc Nephrol. 2011, 6:1786-93. 10.2215\/CJN.01310211","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfac189","article-title":"SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence","volume":"16","author":"Kalay Z","year":"2023","unstructured":"Kalay Z, Sahin OE, Copur S, et al.. SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence. Clin Kidney J. 2023, 16:52-60. 10.1093\/ckj\/sfac189","journal-title":"Clin Kidney J"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2024.12.009","article-title":"Use of SGLT2i in non-diabetic kidney transplant recipients","volume":"57","author":"Quilis A","year":"2025","unstructured":"Quilis A, Gavela E, K\u00e1nter J, et al.. Use of SGLT2i in non-diabetic kidney transplant recipients. Transplant Proc. 2025, 57:24-6. 10.1016\/j.transproceed.2024.12.009","journal-title":"Transplant Proc"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae398","article-title":"Clinically meaningful eGFR slope as a surrogate endpoint differs across CKD stages and slope evaluation periods: the CKD-JAC study","volume":"18","author":"Imaizumi T","year":"2025","unstructured":"Imaizumi T, Komaba H, Hamano T, et al.. Clinically meaningful eGFR slope as a surrogate endpoint differs across CKD stages and slope evaluation periods: the CKD-JAC study. Clin Kidney J. 2025, 18:sfae398. 10.1093\/ckj\/sfae398","journal-title":"Clin Kidney J"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2025.07.292","article-title":"SGLT2 inhibitors reduce the eGFR slope in diabetic and non-diabetic kidney transplant recipients","volume":"25","author":"Rodr\u00edguez-Espinosa D","year":"2025","unstructured":"Rodr\u00edguez-Espinosa D. SGLT2 inhibitors reduce the eGFR slope in diabetic and non-diabetic kidney transplant recipients. Am J Transplant. 2025, 25:S137. 10.1016\/j.ajt.2025.07.292","journal-title":"Am J Transplant"},{"key":"ref53","article-title":"Sodium-glucose transport 2 (SGLT2) inhibitors","author":"Padda IS","year":"2025","unstructured":"Padda IS, Mahtani AU, Parmar M. Sodium-glucose transport 2 (SGLT2) inhibitors. StatPearls (Internet). StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1177\/20420188221090001","article-title":"Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence?","volume":"13","author":"Ujjawal A","year":"2022","unstructured":"Ujjawal A, Schreiber B, Verma A. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence?. Ther Adv Endocrinol Metab. 2022, 13:20420188221090001. 10.1177\/20420188221090001","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref55","article-title":"Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients: The INFINITI Study","author":"Singh S","year":"2025","unstructured":"Singh S. Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients: The INFINITI Study. University Health Network, Toronto; 2025."},{"key":"ref56","article-title":"Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys?","author":"Jenssen T","year":"2025","unstructured":"Jenssen T. Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys?. Oslo University Hospital, Oslo; 2025."},{"key":"ref57","article-title":"Effect of Adding Dapagliflozin to Allograft Dysfunction of Renal Transplanted Patients","author":"University of Sao Paulo General Hospital","year":"2024","unstructured":"University of Sao Paulo General Hospital. Effect of Adding Dapagliflozin to Allograft Dysfunction of Renal Transplanted Patients. University of Sao Paulo General Hospital, Sao Paulo; 2024."},{"key":"ref58","article-title":"The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients","author":"Singh S","year":"2025","unstructured":"Singh S. The Efficacy, Mechanism &amp; Safety of Sodium Glucose Co-Transporter-2 Inhibitor &amp; Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients. Purdue University, West Lafayette; 2025."},{"key":"ref59","article-title":"SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Double-blind, Placebo Controlled, National, Multicenter Trial","author":"Odense University Hospital","year":"2025","unstructured":"Odense University Hospital. SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Double-blind, Placebo Controlled, National, Multicenter Trial. Odense University Hospital, Odense; 2025."},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3390\/transplantology5030022","article-title":"Update on sodium glucose cotransporter type 2 inhibitors use in kidney transplant patients","volume":"5","author":"Salvadori M","year":"2024","unstructured":"Salvadori M, Rosati A, Rosso G. Update on sodium glucose cotransporter type 2 inhibitors use in kidney transplant patients. Transplantology. 2024, 5:224-33. 10.3390\/transplantology5030022","journal-title":"Transplantology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/431224-expanding-the-therapeutic-landscape-sodium-glucose-co-transporter-2-inhibitors-in-kidney-transplant-recipients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:13:31Z","timestamp":1763532811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/431224-expanding-the-therapeutic-landscape-sodium-glucose-co-transporter-2-inhibitors-in-kidney-transplant-recipients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":60,"URL":"https:\/\/doi.org\/10.7759\/cureus.97193","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,18]]}}}